Developmental Funds Building on superb recruitment. core facility development, pilot project productivity, and sparring but effective use of interim support, the Cancer Center requests $700,000 per year in developmental funds for faculty recruitment ($450,000), core facility enhancement ($75,000) and innovative pilot project funding ($175,000). Going forward. the Center does not request funds specifically for interim (bridge) funding but would plan to use. as necessary and with justification, a small portion of the funds for that purpose, To assist with the Center's continued expansion, the budget requests a $50,000 (8%) increase over the current level. The Center's recruitment track record is outstanding. During the past six years, the Center has worked with 16 departments to support recruitment of 29 faculty with CCSG funds. All 29 faculty remain at UNC Chapel Hill and the UNC Lineberger. In 2009, this group of new faculty held ~$17.2 million yearly (total costs) in external funding. The Center also used Developmental Funds to develop five new core services, all of which have been incorporated into CCSG-supported shared resources. Developmental Funds also supported 45 pilot projects awards;40 (89%) had produced a grant award or a publication by 2009. Pilot projects led to more than grant 20 major external funding awards. In addition, an emerging opportunity investment of Developmental Funds became a funded POI focused on DNA damage and repair in melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-37
Application #
8392155
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$442,591
Indirect Cost
$72,664
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Stanley, Christopher C; van der Gronde, Toon; Westmoreland, Kate D et al. (2018) Risk factors and reasons for treatment abandonment among children with lymphoma in Malawi. Support Care Cancer 26:967-973
Dronamraju, Raghuvar; Jha, Deepak Kumar; Eser, Umut et al. (2018) Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. Nucleic Acids Res 46:1331-1344
Koehler, Jennifer W; Miller, Andrew D; Miller, C Ryan et al. (2018) A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. J Neuropathol Exp Neurol 77:1039-1054

Showing the most recent 10 out of 1525 publications